Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
ADC Therapeutics
ADC Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Finance
ADC Therapeutics regains compliance with NYSE continued listing standards
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)
Ingredients
Therapeutic: loncastuximab tesirine for diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer. Up to 40% of patients will require further lines of treatment as their disease relapses or becomes refractory to first line treatment
Pharmaceutical
FDA approves ADC supported by Sterling
ZYNLONTA has been granted accelerated approval by the FDA for use in adult patients with relapsed or refractory B-cell lymphoma (DLBCL)
Ingredients
Synaffix expands collaboration with ADC Therapeutics
ADC has expanded its existing collaboration to explore additional applications of Synaffix' site-specific conjugation technologies
Ingredients
CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer
The antibodies target an overexpressed protein on the surface of some cancer cells, which is not expressed on healthy cells
Research & Development
ADC Therapeutics adds eight new members of staff
As the company continues to expand its pipeline of antibody drug conjugates
Research & Development
QMB welcomes ADC Therapeutics as latest tenant
Novel cancer therapy company’s arrival means QMB is almost full
Subscribe now